JP2023536504A - Ｓｍａｒｃａ２および／またはｓｍａｒｃａ４分解剤としての６置換ピリダジン化合物 - Google Patents

Ｓｍａｒｃａ２および／またはｓｍａｒｃａ４分解剤としての６置換ピリダジン化合物 Download PDF

Info

Publication number
JP2023536504A
JP2023536504A JP2023507923A JP2023507923A JP2023536504A JP 2023536504 A JP2023536504 A JP 2023536504A JP 2023507923 A JP2023507923 A JP 2023507923A JP 2023507923 A JP2023507923 A JP 2023507923A JP 2023536504 A JP2023536504 A JP 2023536504A
Authority
JP
Japan
Prior art keywords
cancer
alkyl
compound
pharmaceutically acceptable
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023507923A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023536504A5 (https=
JPWO2022029617A5 (https=
Inventor
アッビネニ，チャンドラセカール
サマジダル，スサンタ
クイラ，ビラッシュ
ムカルジー，サブヘンドュ
ゴア，スーラジ タチャサヘブ
Original Assignee
オーリジーン オンコロジー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オーリジーン オンコロジー リミテッド filed Critical オーリジーン オンコロジー リミテッド
Publication of JP2023536504A publication Critical patent/JP2023536504A/ja
Publication of JP2023536504A5 publication Critical patent/JP2023536504A5/ja
Publication of JPWO2022029617A5 publication Critical patent/JPWO2022029617A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2023507923A 2020-08-04 2021-08-03 Ｓｍａｒｃａ２および／またはｓｍａｒｃａ４分解剤としての６置換ピリダジン化合物 Pending JP2023536504A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202041033326 2020-08-04
IN202041033326 2020-08-04
PCT/IB2021/057089 WO2022029617A1 (en) 2020-08-04 2021-08-03 6-substituted pyridazine compounds as smarca2 and/or smarca4 degraders

Publications (3)

Publication Number Publication Date
JP2023536504A true JP2023536504A (ja) 2023-08-25
JP2023536504A5 JP2023536504A5 (https=) 2024-08-09
JPWO2022029617A5 JPWO2022029617A5 (https=) 2024-08-09

Family

ID=80117730

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023507923A Pending JP2023536504A (ja) 2020-08-04 2021-08-03 Ｓｍａｒｃａ２および／またはｓｍａｒｃａ４分解剤としての６置換ピリダジン化合物

Country Status (11)

Country Link
US (1) US12570650B2 (https=)
EP (1) EP4192835A4 (https=)
JP (1) JP2023536504A (https=)
KR (1) KR20230061349A (https=)
CN (1) CN116529250A (https=)
AU (1) AU2021320052A1 (https=)
BR (1) BR112023002089A2 (https=)
CA (1) CA3188024A1 (https=)
IL (1) IL300387A (https=)
MX (1) MX2023001445A (https=)
WO (1) WO2022029617A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2021133917A1 (en) 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
BR112022012410A2 (pt) 2019-12-23 2022-08-30 Kymera Therapeutics Inc Degradadores smarca e usos dos mesmos
EP4259144A4 (en) 2020-12-09 2025-08-20 Kymera Therapeutics Inc SMARCA DEGRADING AGENTS AND THEIR USES
WO2025196686A1 (en) * 2024-03-20 2025-09-25 Aurigene Oncology Limited Fused bicyclic compounds as smarca2 and/or smarca4 degraders
CN119874808B (zh) * 2025-01-02 2026-04-17 四川大学 一种靶向smarca蛋白降解的化合物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195201A1 (en) * 2018-04-01 2019-10-10 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
WO2019207538A1 (en) * 2018-04-26 2019-10-31 Aurigene Discovery Technologies Limited Pyridazine derivatives as smarca2/4 degraders
JP2023510746A (ja) * 2020-01-10 2023-03-15 アムジエン・インコーポレーテツド Ｓｍａｒｃａ２－ｖｈｌ分解剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017518348A (ja) * 2014-06-20 2017-07-06 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ Ｉｒａｋ４阻害剤としての置換インダゾール化合物
JP6815318B2 (ja) 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
MA41598A (fr) 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017011371A1 (en) * 2015-07-10 2017-01-19 Arvinas, Inc Mdm2-based modulators of proteolysis and associated methods of use
EP3337476A4 (en) * 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
KR20190140438A (ko) * 2017-02-28 2019-12-19 에피자임, 인코포레이티드 암 치료를 위한 smarca2의 저해

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195201A1 (en) * 2018-04-01 2019-10-10 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
WO2019207538A1 (en) * 2018-04-26 2019-10-31 Aurigene Discovery Technologies Limited Pyridazine derivatives as smarca2/4 degraders
JP2023510746A (ja) * 2020-01-10 2023-03-15 アムジエン・インコーポレーテツド Ｓｍａｒｃａ２－ｖｈｌ分解剤

Also Published As

Publication number Publication date
EP4192835A4 (en) 2024-08-21
US20240018134A1 (en) 2024-01-18
EP4192835A1 (en) 2023-06-14
WO2022029617A1 (en) 2022-02-10
CN116529250A (zh) 2023-08-01
KR20230061349A (ko) 2023-05-08
MX2023001445A (es) 2023-05-08
BR112023002089A2 (pt) 2023-02-28
CA3188024A1 (en) 2022-02-10
AU2021320052A1 (en) 2023-03-23
US12570650B2 (en) 2026-03-10
IL300387A (en) 2023-04-01

Similar Documents

Publication Publication Date Title
JP2023536504A (ja) Ｓｍａｒｃａ２および／またはｓｍａｒｃａ４分解剤としての６置換ピリダジン化合物
US12371426B2 (en) Pyridazine derivatives as SMARCA2/4 degraders
KR102142177B1 (ko) Ezh2 억제용 하이드로클로라이드 염 형태
JP2021525219A (ja) がんに対する使用のための、ｅｇｆｒの分解を引き起こす化合物
WO2014134774A1 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
CN103402995B (zh) 吲哚、吲唑衍生物或其盐
JP2023513373A (ja) Ｐ２ｘ３修飾薬
WO2021041970A1 (en) Perk inhibiting imidazolopyrazine compounds
KR20190120786A (ko) 디히드로오로테이트 옥시게나제 억제제로서의 1,4,6-삼치환된-2-알킬-1H-벤조[d]이미다졸 유도체
KR20220068224A (ko) Perk 억제 화합물
WO2024214019A1 (en) Tetracyclic compounds as smarca2 and/or smarca4 degraders
EP3617204A1 (en) Indoleamine 2,3-dioxygenase inhibitor and application
JP2026503938A (ja) Ｃｙｐ１１ａ１阻害剤化合物ならびにその調製方法およびその使用
WO2021195183A1 (en) Compositions and methods for inhibiting protein embryonic ectoderm development activity and treating disease
AU2011274903B2 (en) Substituted pyridine compound
EA052684B1 (ru) 6​-замещенные пиридазиновые соединения в качестве деструкторов smarca2 и/или smarca4
JP2025506452A (ja) Ｓｍａｒｃａ２及び／又はｓｍａｒｃａ４分解剤としての３－置換ピリダジン化合物
RU2845145C1 (ru) Соединения для подавления рака с мутацией egfr и их фармацевтическое применение
WO2025094065A1 (en) Amino-substituted pyridazine compounds as smarca2 and/or smarca4 degraders
KR20250170567A (ko) 치환된 아세틸렌 화합물 유도체 및 이의 약제학적 용도
WO2025196686A1 (en) Fused bicyclic compounds as smarca2 and/or smarca4 degraders
HK40029737A (en) Compounds which cause degradation of egfr, for use against cancer
HK1189384B (en) Indole or indazole derivative or salt thereof
NZ626745A (en) Cyclic amide derivatives as inhibitors of 11 - beta - hydroxysteroid dehydrogenase and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240801

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240801

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250515

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250904

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260106

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260406